Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in HCC with Impaired Liver Function
NCT04454762Phase 2Unknown
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Jul 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Johannes Gutenberg University Mainz. Status: unknown.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04454762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454762.